产品
编 号：F269665
分子式：C25H34F2O5
分子量：452.53
分子式：C25H34F2O5
分子量：452.53
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
2mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 209860-87-7
产品详情
生物活性：
Tafluprost (AFP-168) is an anti-glaucoma prostaglandin (PG) analog. Tafluprost can inhibit the apoptosis of retinal ganglion cells (RGCs) and rat RGCs cells. Tafluprost promotes axon regeneration by regulating Zn2+-mTORpathway, inhibits intracellular lipid accumulation in human preorbital adipocytes. Tafluprost can be used in the study of optic nerve injury in glaucoma.
体内研究：
Tafluprost (0.0015% AFP168 滴眼液，连用14 天) 在雄性 Sprague-Dawley 大鼠中降低视神经挤压 (ONC) 眼压，提高 RGC 细胞活力，减少视网膜神经细胞凋亡。Animal Model:Male Sprague rat model
Dosage:0.0015%
Administration:Via eye drops
Result:Increased the number of RGCs and reduced the number of TUNEL-positive cells.
Animal Model:Prostaglandin receptor deletion C57BL/6 mice model
Dosage:3 μL (0.0015% Tafluprost)
Administration:Instillation; Single dose
Result:Reduced IOP in WT, EP1KO, EP2KO, EP3KO and FPKO mice, and the average IOP reduction rates were 25.8(2.1)%, 26.3(0.8)%, 24.2(1.4)%, 16.5(1.7)% and 20.9(1.5)%, respectively. (The decrease of IOP in EP3KO and FPKO mice was less than that in WT mice.)
体外研究：
Tafluprost (3 μM, 48 h) 在 RGC-5 细胞中减少细胞凋亡数量。Tafluprost (0.1-100 μM, 48 h) 在 RGC-5 细胞中以剂量依赖性的方式增强细胞活力。
Tafluprost (AFP-168) is an anti-glaucoma prostaglandin (PG) analog. Tafluprost can inhibit the apoptosis of retinal ganglion cells (RGCs) and rat RGCs cells. Tafluprost promotes axon regeneration by regulating Zn2+-mTORpathway, inhibits intracellular lipid accumulation in human preorbital adipocytes. Tafluprost can be used in the study of optic nerve injury in glaucoma.
体内研究：
Tafluprost (0.0015% AFP168 滴眼液，连用14 天) 在雄性 Sprague-Dawley 大鼠中降低视神经挤压 (ONC) 眼压，提高 RGC 细胞活力，减少视网膜神经细胞凋亡。Animal Model:Male Sprague rat model
Dosage:0.0015%
Administration:Via eye drops
Result:Increased the number of RGCs and reduced the number of TUNEL-positive cells.
Animal Model:Prostaglandin receptor deletion C57BL/6 mice model
Dosage:3 μL (0.0015% Tafluprost)
Administration:Instillation; Single dose
Result:Reduced IOP in WT, EP1KO, EP2KO, EP3KO and FPKO mice, and the average IOP reduction rates were 25.8(2.1)%, 26.3(0.8)%, 24.2(1.4)%, 16.5(1.7)% and 20.9(1.5)%, respectively. (The decrease of IOP in EP3KO and FPKO mice was less than that in WT mice.)
体外研究：
Tafluprost (3 μM, 48 h) 在 RGC-5 细胞中减少细胞凋亡数量。Tafluprost (0.1-100 μM, 48 h) 在 RGC-5 细胞中以剂量依赖性的方式增强细胞活力。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备